---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-065305"
form_type: "8-K"
ticker: "CVKD"
cik: "0001937993"
company_name: "Cadrenal Therapeutics, Inc."
filed_at: "2023-08-10T23:59:59+00:00"
generated_at: "2026-06-11T19:37:29.120764+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Cadrenal Therapeutics Q2 2023 update; cash $9.6M, tecarfarin expansion into LVADs

## Summary
- Q2 2023 operating expenses (excl. non-cash) totaled $835,000; cash balance $9.6M as of Aug 14.
- Completed $7.5M private placement at $1.75 per share with an institutional investor.
- Expanded tecarfarin development to LVAD patients; estimated $600M annual U.S. addressable market.
- Appointed cardiovascular executive Robert Lisicki to the board of directors.
- Combined addressable market for ESKD/AFib and LVADs estimated at $1.6B annually in U.S.

## SEC filing metadata
- accession: 0001213900-23-065305
- form_type: 8-K
- ticker: CVKD
- cik: 0001937993
- company_name: Cadrenal Therapeutics, Inc.
- filed_at: 2023-08-10T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1937993/000121390023065305/0001213900-23-065305-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1937993/000121390023065305/ea183225-8k_cadrenal.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-065305
- JSON: https://secwatch.observer/filing/0001213900-23-065305.json
- Plain text: https://secwatch.observer/filing/0001213900-23-065305.txt

## Key facts
- Earnings Releases
  Cadrenal Therapeutics, Inc. reported financial results for the quarter ended June 30, 2023.
  - Period: the quarter ended June 30, 2023
  - Result: reported results
  source text: issued a press release that included financial information for the fiscal quarter ended June 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1937993/000121390023065305/0001213900-23-065305-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.